RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug-Reference-Cited by-同舟云学术

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug

Published:2015-06-11 Issue:24 Volume:125 Page:3760-3768
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wermke Martin¹²^ORCID,Camgoz Aylin³,Paszkowski-Rogacz Maciej³,Thieme Sebastian⁴,von Bonin Malte¹⁵⁶,Dahl Andreas⁷,Platzbecker Uwe¹,Theis Mirko³,Ehninger Gerhard¹,Brenner Sebastian⁴,Bornhäuser Martin¹,Buchholz Frank³⁵⁶⁸

Affiliation:

1. Universitätsklinikum Carl Gustav Carus der Technischen Universität, Medizinische Klinik und Poliklinik I, Dresden, Germany;

2. Early Clinical Trial Unit and

3. Medizinische Systembiologie, Medizinische Fakultät der Technischen Universität, Universitäts KrebsCentrum, Dresden, Germany;

4. Universitätsklinikum Carl Gustav Carus der Technischen Universität, Klinik und Poliklinik für Pädiatrie, Dresden, Germany;

5. German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany;

6. German Cancer Research Center, Heidelberg, Germany;

7. Deep-Sequencing Facility Sonderforschungsbereich 655, Biotechnology Center, Technische Universität Dresden, Dresden, Germany;

8. German Cancer Research Center (DKFZ), Heidelberg, Germany

Abstract

Key Points Large-scale loss-of-function RNAi screens in patient-derived AML cells are feasible and able to pinpoint therapeutic targets. ROCK1 inhibition exerts antileukemic effects in primary human AML cells in vitro and in vivo.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/24/3760/1387332/3760.pdf

Reference49 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.;Hochhaus;Leukemia,2009

2. Anthracycline dose intensification in acute myeloid leukemia.;Fernandez;N Engl J Med,2009

3. Reduced mortality after allogeneic hematopoietic-cell transplantation.;Gooley;N Engl J Med,2010

4. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm—combined prospective analysis by the German AML Intergroup.;Büchner;J Clin Oncol,2012

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting SRSF2 mutations in leukemia with RKI-1447: A strategy to impair cellular division and nuclear structure;iScience;2024-04

2. AGO2-RIP-Seq reveals miR-34/miR-449 cluster targetome in sinonasal cancers;PLOS ONE;2024-01-12

3. Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy;World Journal of Surgical Oncology;2023-09-27

4. WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub of Tumorigenesis and a Novel Therapeutic Target;International Journal of Molecular Sciences;2023-08-06

5. Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition;Cell Communication and Signaling;2023-06-14